RESUMEN
Pyroptosis, a form of programmed cell death with a high pro-inflammatory effect, causes cell lysis and leads to the secretion of countless interleukin-1ß (IL-1ß) and IL-18 cytokines, resulting in a subsequent extreme inflammatory response through the caspase-1-dependent pathway or caspase-1-independent pathway. Adult-onset Still's disease (AOSD) is a systemic inflammatory disease with extensive disease manifestations and severe complications such as macrophage activation syndrome, which is characterized by high-grade inflammation and cytokine storms regulated by IL-1ß and IL-18. To date, the pathogenesis of AOSD is unclear, and the available therapy is unsatisfactory. As such, AOSD is still a challenging disease. In addition, the high inflammatory states and the increased expression of multiple pyroptosis markers in AOSD indicate that pyroptosis plays an important role in the pathogenesis of AOSD. Accordingly, this review summarizes the molecular mechanisms of pyroptosis and describes the potential role of pyroptosis in AOSD, the therapeutic practicalities of pyroptosis target drugs in AOSD, and the therapeutic blueprint of other pyroptosis target drugs.
Asunto(s)
Enfermedad de Still del Adulto , Adulto , Humanos , Enfermedad de Still del Adulto/tratamiento farmacológico , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/patología , Interleucina-18 , Piroptosis , Citocinas , Biomarcadores , Caspasa 1Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Insuficiencia Cardíaca , Miocarditis , Enfermedad de Still del Adulto , Adulto , Humanos , COVID-19/complicaciones , Vacunas contra la COVID-19/efectos adversos , Insuficiencia Cardíaca/complicaciones , Miocarditis/complicaciones , Choque Cardiogénico/complicaciones , Enfermedad de Still del Adulto/etiología , VacunaciónRESUMEN
Since December 2020, coronavirus disease 2019 (COVID-19) vaccines have been distributed in most countries to prevent the onset and aggravation of COVID-19. There is little information regarding the long-term safety of the vaccines. We report three cases and a literature review of new-onset adult-onset Still's disease (AOSD) that occurred following COVID-19 vaccination. Our cases include moderate to severe AOSD, and two were complicated with macrophage activation syndrome. Seventeen cases of new-onset or relapse of AOSD following COVID-19 vaccination, including 14 identified in the literature review and our 3 patients, were all treated successfully with glucocorticoid therapy, immunosuppressive drugs, or biologic agents.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Enfermedad de Still del Adulto , Adulto , Humanos , COVID-19/complicaciones , Vacunas contra la COVID-19/efectos adversos , Inmunosupresores/efectos adversos , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/complicaciones , Vacunación/efectos adversosAsunto(s)
Vacunas contra la COVID-19 , Enfermedad de Still del Adulto , Adulto , Humanos , ChAdOx1 nCoV-19 , Vacunas contra la COVID-19/efectos adversos , Enfermedad de Still del Adulto/tratamiento farmacológico , Enfermedad de Still del Adulto/etiología , Vacunación/efectos adversos , COVID-19/prevención & controlRESUMEN
The upheaval caused by the coronavirus disease 2019 (COVID-19) pandemic has allowed to large population to use new vaccines urgently. Although vaccine development programs and available epidemiological data reassure us, there are concerns about specific risks associated with vaccinations in patients with autoimmune-autoinflammatory diseases. These patients have the potential to decrease humoral and cellular immune responses caused by biologic agents and develop an acute flare of underlying disease following vaccination. We herein present a rare case of a 49-year-old female with a flare of adult-onset Still's disease (AOSD) after the first dose of BNT162b2 mRNA COVID-19 vaccination. She had been diagnosed with AOSD 7 years earlier and had achieved remission with tocilizumab. This patient came to the emergency room with fever and nausea that occurred 4 days after the first vaccination. Based on laboratory results and clinical manifestations, we suspected AOSD flare and was treated with steroid pulse therapy. In this report, we also discuss possible mechanisms linking vaccination with a flare of AOSD. Considering the close time relationship between COVID-19 vaccinations and a flare of AOSD, physicians should be aware of adverse events from this new vaccination and evaluate the benefits and risks of vaccination for each patient. KEY POINTS: ⢠COVID-19 vaccination may cause an AOSD flare in patients who are in remission with tocilizumab.
Asunto(s)
COVID-19 , Enfermedad de Still del Adulto , Adulto , Vacuna BNT162 , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , ARN Mensajero , Enfermedad de Still del Adulto/complicaciones , Enfermedad de Still del Adulto/etiología , Vacunación/efectos adversosRESUMEN
The current SARS-CoV-2 pandemic diffused worldwide has encouraged the rapid development of vaccines to counter the spread of the virus. At present in Italy, 75.01% of the population completed the vaccination course (AIFA.gov.it) and very few adverse events have been recorded by now. Side-effects related to a theoretical over-reaction of the immune system in response to vaccines administration have been described, and the possibility that an autoimmune or a hyperinflammatory condition may occur was recently observed. Herein, we report four cases of hyperinflammatory syndrome with features indicative of Adult-onset Still's disease (AOSD) and macrophage activation syndrome (MAS), occurred after anti-SARS-CoV-2 vaccine injection and seen at our Unit between March and May 2021. Since interleukin (IL)-1 is one of the pivotal cytokines involved in AOSD pathogenesis, the inhibition of IL-1 is crucial in ameliorating the clinical symptoms of those patients. Moreover, it has been highlighted the central role of IL-1 as a hallmark of the hyperinflammatory status elicited by SARS-CoV-2 infection. In this case series, we successfully employed the IL-1 receptor antagonist anakinra to curb the cytokine release likely unleashed by the vaccine stimulation in potentially predisposed subjects. We also made a literature search to detect other patients with hyperinflammation temporally related to vaccines injection who benefited from IL-1 inhibition, while other AOSD/MAS-like described syndromes improved with other immunomodulatory strategies.
Asunto(s)
Vacunas contra la COVID-19/efectos adversos , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Vacunas de ARNm/efectos adversos , Vacuna BNT162/efectos adversos , ChAdOx1 nCoV-19/efectos adversos , Femenino , Humanos , Interleucina-1/inmunología , Interleucina-1/metabolismo , Masculino , Persona de Mediana Edad , Enfermedad de Still del Adulto/inducido químicamente , Enfermedad de Still del Adulto/etiología , Vacunas de ADN/efectos adversosRESUMEN
Vaccination is a cornerstone for reducing the risk of COVID-19 infection during a pandemic. Although the currently used COVID-19 vaccine is considered safe, some concerns persist regarding the likelihood of flares of rheumatic diseases. Still's disease is a rare auto-inflammatory disorder of unknown etiology, and the data on the flare of Still's disease following COVID-19 vaccination are limited. Therefore, we hereby present the case of a 34-year-old female patient with Still's disease who experienced a flare after a ChAdOx1 nCoV-19 vaccination. The patient visited the emergency department complaining of fever, arthralgia, myalgia, pleuritic chest pain and macular salmon-pink rash on her back for the past 2 days. She had maintained low Still's disease activity with etanercept and low-dose glucocorticoid for 14 years. She received the ChAdOx1 nCoV-19 vaccine 7 days before the flare. Laboratory investigations revealed leucocytosis and elevated serum levels of erythrocyte sedimentation rate, C-reactive protein, and ferritin. Computed tomography showed no specific findings. She received methylprednisolone pulse therapy, etanercept, and methotrexate for treating the Still's disease flare. However, her symptoms were not fully controlled, and she developed pericarditis, pleuritis, fever and macular rashes expanding to her extremities. After excluding infectious conditions by blood culture and pleural fluid analysis, we administered tocilizumab with methotrexate and prednisolone. Her symptoms and laboratory findings improved significantly, and she was discharged without symptoms 7 days later. Although rare, this case of a patient with Still's disease undergoing a flare following vaccination suggests that close observation of disease activity is warranted following COVID-19 vaccination.
Asunto(s)
COVID-19 , Enfermedad de Still del Adulto , Adulto , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , ChAdOx1 nCoV-19 , Femenino , Humanos , Enfermedad de Still del Adulto/diagnóstico , Enfermedad de Still del Adulto/tratamiento farmacológico , Enfermedad de Still del Adulto/etiología , VacunaciónRESUMEN
The coronavirus disease 2019 (COVID-19) pandemic is being overcome by widespread inoculation with various COVID-19 vaccines, but concerns about the safety of the vaccines are a major hurdle to widespread vaccination. We report the first case of adult-onset Still's disease (AOSD) developing in a 36-year-old, previously healthy woman after the first dose of BNT162b2 mRNA COVID-19 vaccine (Pfizer). She visited our hospital due to high spiking fever and sore throat that developed 10 days after vaccination. Based on thorough investigations and changes in symptoms and signs after admission, she was diagnosed with AOSD and treated with high dose steroids and tocilizumab. This report suggests the possibility that AOSD could be triggered by COVID-19 vaccines through activation of the innate immune system.
Asunto(s)
Vacuna BNT162/efectos adversos , Enfermedad de Still del Adulto/etiología , Vacunación/efectos adversos , Adulto , Femenino , Humanos , Inmunidad Innata , Enfermedad de Still del Adulto/tratamiento farmacológicoAsunto(s)
Vacuna BNT162/administración & dosificación , COVID-19/prevención & control , SARS-CoV-2/efectos de los fármacos , Enfermedad de Still del Adulto/diagnóstico , Adulto , Vacuna BNT162/efectos adversos , Vacuna BNT162/inmunología , COVID-19/virología , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , ARN Mensajero/genética , ARN Mensajero/inmunología , SARS-CoV-2/inmunología , SARS-CoV-2/fisiología , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/terapia , Vacunación/efectos adversos , Vacunación/métodosRESUMEN
Modulation of miRNAs and neutrophil extracellular traps (NETs) formation are both implicated in inflammatory disorders. Adult-onset Still's disease (AOSD) is a systemic autoinflammatory disease with neutrophilic leukocytosis and unknown etiology. Although the NETs formation is elevated in AOSD patients, the regulatory roles of miRNAs in NETs formation in AOSD remains unclear. We revealed that the circulating levels of IL-18, NETs, and miR-223 were significantly higher in active AOSD patients, compared with inactive AOSD patients or healthy controls (P < 0.005). Moreover, IL-18 increased calcium influx into neutrophils, which led to mitochondrial ROS (mROS) production and NETs formation. Elevated levels of NETs-DNA could induce miR-223 expression in neutrophils through activating Toll-like receptor 9. The upregulated miR-223 expression in neutrophils suppressed mROS production by blocking calcium influx, and subsequently inhibited IL-18-mediated NETs formation. Besides, the increased neutrophil-derived exosomal miR-223 levels were observed in active AOSD patients compared with healthy controls (P < 0.005). Our in vitro assays demonstrated that the neutrophil-derived small extracellular vesicles carried miR-223, which could repress IL-18 production in macrophages. Together, these results suggest a fine-tuned mechanism between inflammatory (IL-18 induced NETs) and anti-inflammatory (miR-223) factors in AOSD. MiR-223, mROS inhibitors, and calcium channel blockers are the potential therapeutics for autoinflammatory diseases such as AOSD.
Asunto(s)
Calcio/metabolismo , Trampas Extracelulares/genética , Vesículas Extracelulares/metabolismo , MicroARNs/genética , Neutrófilos/metabolismo , Susceptibilidad a Enfermedades , Regulación de la Expresión Génica , Humanos , Interleucina-18/metabolismo , Macrófagos/metabolismo , Mitocondrias/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/metabolismoRESUMEN
Adult-onset Still's disease (AOSD) is a systemic, multifactorial, autoinflammatory disease for which the etiopathogenesis is not well understood. Given the similarities in clinical and laboratory features between this disease and sepsis, and the differences in treatment strategies for these two diseases, specific diagnostic markers are crucial for the correct diagnosis and management of AOSD. Previous studies have shown plasma heparin-binding protein (HBP) is a promising potential biomarker for AOSD; thus, this study aimed to detect serum HBP levels in patients with AOSD or sepsis to assess its potential as a biomarker for differential diagnosis. We found that serum HBP levels were significantly higher in patients with active AOSD than that in those with inactive AOSD. Patients with sepsis had higher serum HBP levels compared with those who had active or inactive AOSD. We calculated the area under the receiver operating characteristic (ROC) curve to assess whether HBP could be used to differentiate active from inactive AOSD; this was 0.811 with sensitivity 0.650, specificity 0.811, and cutoff HBP value of 35.59 ng/ml. The area under the ROC curve for HBP as a biomarker to differentiate AOSD from sepsis was 0.653, with sensitivity 0.759, and specificity 0.552, and cutoff HBP value of 65.1 ng/ml. Taken together, the results of our study suggest that serum HBP could be a useful diagnostic biomarker to evaluate disease activity in patients with AOSD, and to differentiate AOSD from sepsis.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/sangre , Biomarcadores/sangre , Sepsis/sangre , Sepsis/diagnóstico , Enfermedad de Still del Adulto/sangre , Enfermedad de Still del Adulto/diagnóstico , Adulto , Proteínas Sanguíneas , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Curva ROC , Valores de Referencia , Índice de Severidad de la Enfermedad , Enfermedad de Still del Adulto/etiología , Adulto JovenRESUMEN
Approximately 30% to 40% of all patients with adult-onset Still disease (AOSD) experience relapses, sometimes presenting as chronic damage, and these events can subsequently increase the morbidity and mortality in patients with AOSD. However, few studies are investigating the factors related to relapse in such patients. Therefore, this study aimed to explore the risk factors associated with relapse of AOSD.This cohort study enrolled 112 AOSD patients who satisfied the Yamaguchi criteria and obtained available data from Chonnam National University Hospital. The demographic, clinical, and laboratory data as well as treatment history of the patients from January 2008 to December 2019 were retrospectively reviewed. Relapse events were defined as the presence of one or more recurrent events. Multivariate logistic regression analysis was performed to investigate the possible risk factors for relapse.During a mean follow-up of 103.3 months, 47 of 112 patients (41.9%) developed a relapse. According to the results of multivariate logistic regression analysis, arthritis (odds ratio [OR]â=â19.530, 95% confidence interval [CI]: 5.047-75.582, Pâ<â.001) and lymphadenopathy (ORâ=â6.539, 95% CI: 2.329-18.358, Pâ<â.001) predicted the development of recurrent events in patients with AOSD.Patients with AOSD had frequent relapses during the clinical course of their disease. Risk factors associated with flares were the presence of arthritis and lymphadenopathy.
Asunto(s)
Enfermedad de Still del Adulto/etiología , Adulto , Artritis/complicaciones , Femenino , Humanos , Modelos Logísticos , Linfadenopatía/complicaciones , Masculino , Persona de Mediana Edad , Recurrencia , República de Corea/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Enfermedad de Still del Adulto/epidemiologíaRESUMEN
Objective: This study aimed to investigate the distributions of lymphocytes in adult onset Still's disease (AOSD) with liver dysfunction, and further prospectively explore whether receptor interacting serine/threonine kinases (RIPKs) in lymphocytes play a role in the pathogenesis of AOSD especially liver involvement. Methods: Seventy-two AOSD patients and 19 cases of healthy controls (HCs) were retrospectively reviewed, the AOSD group was then divided into liver damage (LD) group and non-liver damage (NLD) group, and the distributions of lymphocytes in peripheral blood were analyzed. Another independent 24 AOSD patients and 20 HCs were recruited for prospective study of RIPKs; the RIPKs in peripheral blood lymphocytes were detected by flow cytometry. Liver biopsy specimens were obtained from two AOSD patients and underwent immunochemistry analysis with RIPK1 and RIPK3 antibody. Results: In the retrospective study, AOSD showed significantly abnormal lymphocytes distributions, and disease activity was positively correlated with percentage of CD3+ T cells. LD patients were younger in age and showed higher disease activity score than NLD patients; they had higher frequencies of CD3+ T cells, especially higher CD8+ T cells (all p<0.05). In the prospective study, RIPKs in lymphocytes were significantly higher in AOSD patients than that of HCs, and LD patients also showed higher RIPKs expression than NLD patients. In addition, RIPKs were positively correlated with erythrocyte sedimentation rate (ESR) and disease activity in AOSD patients and LD and NLD subgroups (all p<0.05). Further, RIPKs expression was confirmed in two AOSD patients' liver. ROC curve analysis indicated that RIPKs in lymphocytes (%) could be potential biomarkers in the diagnosis of AOSD and liver damage. Conclusions: Abnormal lymphocytes distributions and RIPKs expression were detected in AOSD. Aberrant expression of RIPKs in lymphocytes might be involved in the pathogenesis of AOSD. RIPKs could be candidate markers for AOSD and liver damage.
Asunto(s)
Hígado/metabolismo , Hígado/patología , Proteína Serina-Treonina Quinasas de Interacción con Receptores/metabolismo , Enfermedad de Still del Adulto/metabolismo , Enfermedad de Still del Adulto/patología , Inmunidad Adaptativa , Adulto , Biomarcadores , Estudios de Casos y Controles , Susceptibilidad a Enfermedades , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Inmunofenotipificación , Linfocitos/inmunología , Linfocitos/metabolismo , Masculino , Persona de Mediana Edad , Fenotipo , Curva ROC , Proteína Serina-Treonina Quinasas de Interacción con Receptores/genética , Índice de Severidad de la Enfermedad , Enfermedad de Still del Adulto/etiología , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismoRESUMEN
Macrophage activation syndrome (MAS) is a form of secondary hemophagocytic lymphohistiocytosis (HLH) and is a life-threatening complication of adult-onset Still disease. MAS has been usually treated with high-dose glucocorticoid with additional immunosuppressive agents, such as cyclosporine. Etoposide has been used for the treatment of severe refractory MAS based on the successful results of HLH-2004 protocol in patients with mostly primary form of HLH. We herein describe a case of severe refractory MAS secondary to adult-onset Still disease in an elderly woman that inadequately responded to etoposide but remarkably responded to additional tocilizumab. Furthermore, short-term tocilizumab led her into remission and enabled tapering off glucocorticoids after 15 months. Tocilizumab may be effective for the treatment of refractory HLH after the failure of the etoposide-containing induction regimen.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Síndrome de Activación Macrofágica/complicaciones , Síndrome de Activación Macrofágica/tratamiento farmacológico , Terapia Molecular Dirigida , Enfermedad de Still del Adulto/complicaciones , Enfermedad de Still del Adulto/tratamiento farmacológico , Ciclosporina/administración & dosificación , Resistencia a Medicamentos , Quimioterapia Combinada , Etopósido/administración & dosificación , Glucocorticoides/administración & dosificación , Humanos , Inmunosupresores/administración & dosificación , Síndrome de Activación Macrofágica/diagnóstico , Índice de Severidad de la Enfermedad , Enfermedad de Still del Adulto/diagnóstico , Enfermedad de Still del Adulto/etiología , Resultado del TratamientoRESUMEN
This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still's disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.
Asunto(s)
Antirreumáticos/uso terapéutico , Enfermedades Autoinmunes/tratamiento farmacológico , Azetidinas/uso terapéutico , Inflamación/tratamiento farmacológico , Purinas/uso terapéutico , Pirazoles/uso terapéutico , Enfermedad de Still del Adulto/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Adulto , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/etiología , Azetidinas/administración & dosificación , Azetidinas/efectos adversos , Femenino , Humanos , Inflamación/diagnóstico , Inflamación/etiología , Masculino , Purinas/administración & dosificación , Purinas/efectos adversos , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Enfermedad de Still del Adulto/diagnóstico , Enfermedad de Still del Adulto/etiología , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Resultado del TratamientoRESUMEN
Adult-onset Still's disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology. AOSD is generally characterized by high spiking fever, arthralgia or arthritis, skin rash, leukocytosis, and hyperferritinemia. Traditionally, AOSD has been treated with non-steroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. An increasing number of studies have shown that proinflammatory cytokines, such as interleukin-1ß, -18, -6, and tumor necrosis factor-α, play key roles in AOSD and may serve as therapeutic targets. In the current review, we provided insights into the roles of these cytokines in the pathogenesis of AOSD and also provided a commentary on the clinical studies of biologic therapy against AOSD.
Asunto(s)
Autoinmunidad , Susceptibilidad a Enfermedades , Terapia Molecular Dirigida , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/terapia , Enfermedades Autoinmunes , Biomarcadores , Citocinas/metabolismo , Manejo de la Enfermedad , Susceptibilidad a Enfermedades/inmunología , Humanos , Enfermedad de Still del Adulto/diagnóstico , Enfermedad de Still del Adulto/epidemiologíaRESUMEN
Introduction: Adult-onset Still's disease (AOSD) is a systemic inflammatory disease, which presents itself as an adult form of systemic juvenile idiopathic arthritis. Innate immune activation driven by a combination of genetic and environmental factors is the primary mechanism underlying disease pathogenesis in AOSD patients. Few biomarkers have been identified for AOSD diagnosis or for the assessment of disease activity or prediction of clinical outcomes. Damage-associated molecular patterns (DAMPs) can activate innate immunity, resulting in tissue damage. Changes in several DAMPs are associated with disease pathogenesis in AOSD patients. Areas covered: This review describes the role of DAMPs in AOSD pathogenesis and discusses their potential for use as disease biomarkers. Together with overall pathogenesis of AOSD, high-mobility group box-1, advanced glycation end products, S100 proteins, and neutrophil extracellular traps are introduced and discussed in detail. Expert opinion: The activation of macrophages and neutrophils is associated with several DAMPs, causing high concentrations of proinflammatory cytokines in AOSD patients. Involvement of certain DAMPs in AOSD patients is well documented due to the presence of sterile inflammation; however, direct evidence for some DAMPs is lacking. Further research into the role of DAMP molecules in AOSD patients may reveal new biomarkers and provide targets for disease intervention.
Asunto(s)
Alarminas/genética , Alarminas/metabolismo , Biomarcadores , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/metabolismo , Adulto , Calgranulina A/genética , Calgranulina A/metabolismo , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Femenino , Humanos , Inmunohistoquímica , Oportunidad Relativa , Enfermedad de Still del Adulto/diagnósticoRESUMEN
Previous studies have revealed that several micro-organisms, especially DNA viruses, have been associated with adult-onset Still's disease (AOSD). However, there are no studies on the relationship between the presence of viral infections in AOSD patients with disease occurrence and reactivation. In the present study, we aimed to investigate the presence of antibodies against virus, virus DNA load and nucleic acid sensors in AOSD patients. Anti-viral antibodies were measured by enzyme-linked immunosorbent assay (ELISA) in plasma samples from 100 AOSD patients and 70 healthy controls (HCs). The copy number of cytomegalovirus (CMV) DNA in 100 AOSD patients was detected by PCR. The expression levels of nucleic acid sensors interferon gamma-inducible protein 16 (IFI16) and absent in melanoma 2 (AIM2) in peripheral blood mononuclear cell (PBMC) and skin from AOSD patients and HCs were analyzed by PCR and immunohistochemistry. The levels of antibodies against CMV were significantly higher in AOSD patients compared to HCs. Moreover, the level of anti-CMV IgM antibody was significantly increased in patients with fever, sore throat, arthralgia and rash. CMV DNA was found in plasma of AOSD patients with disease new-onset and relapse. Furthermore, the copy number of CMV DNA significantly increased in patients with fever, sore throat, arthralgia and rash. And the significant associations of the CMV DNA level with the levels of leukocytes, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were observed. Moreover, we found an upregulation of cytoplasmic DNA-sensing receptor IFI16 and AIM2 in PBMC and skin from AOSD patients. In conclusion, our results showed that CMV infection may play a role in the initiation or amplification of inflammatory responses in AOSD.
Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/virología , Citomegalovirus , Susceptibilidad a Enfermedades , Enfermedad de Still del Adulto/etiología , Enfermedad de Still del Adulto/patología , Adulto , Anticuerpos Antivirales/inmunología , Biomarcadores , Citocinas/metabolismo , Citomegalovirus/inmunología , Infecciones por Citomegalovirus/inmunología , Femenino , Humanos , Inmunoglobulina G/inmunología , Inmunoglobulina M/inmunología , Masculino , Persona de Mediana Edad , Fenotipo , Recurrencia , Enfermedad de Still del Adulto/metabolismo , Carga Viral , Adulto JovenRESUMEN
BACKGROUND: Few studies have reported the long-term clinical outcome of patients discharged with undiagnosed fever of unknown origin (FUO). In this study, the clinical features and outcomes of patients with unexplained fever were explored to improve our understanding of FUO. METHOD: Patients diagnosed with FUO at admission and discharged without final diagnoses after systematic examination in the department of infectious diseases at Peking Union Medical College Hospital between 2004 and 2010 were followed up by telephone. Medical records were reviewed, and the clinical features and outcomes of patients for whom follow-up data were available were summarized. RESULTS: Between 2004 and 2010, 58 patients with follow-up data, who were diagnosed with FUO at admission and did not have a final diagnosis at discharge, were enrolled in this study. The median duration of follow-up was 518 (0.4-830) weeks, and the fever duration was 24.6 (6.7-763.2) weeks. Final diagnoses were established in 11 cases (19%), and the diagnostic methods included clinical diagnosis, diagnostic therapy, genetic screening and biopsy pathology. The fever in 35 patients (60%) subsided during hospitalization or after discharge. Their condition was stable and self-limited after long-term follow-up, and they were ultimately thought to be cured. Two patients had periodic fever during prolonged observation: one patient needed intermittent use of nonsteroidal antiinflammatory drugs (NSAIDs), and the other needed intermittent use of NSAIDs and a steroid. Ten patients died during follow-up, with 9 deaths being caused by severe and worsening conditions related to the febrile illness. CONCLUSIONS: Long-term follow-up should be performed for patients with undiagnosed FUO. Some patients can obtain a definitive diagnosis by repeated multiple invasive examinations and diagnostic treatment. Most patients have a self-limited illness, and their prognosis is good.